BACKGROUND: Adults with metastatic Ewing family sarcomas (ES) after being treated with standard therapy for localised disease have limited treatment options with curative intent. The aim of this retrospective single centre study was to evaluate the efficacy of autologous stem cell transplantation (ASCT) in this patient population. METHODS: We report on seven consecutive patients with ES. Four patients with initial localised disease developed distant metastases after being treated with initial standard pre-operative chemotherapy followed by surgery and subsequent standard post-operative chemotherapy. Three patients with initial metastatic disease were pre-treated with standard polychemotherapy. All patients received high-dose chemotherapy (HDCT) followed by ASCT for metastatic disease. RESULTS: For patients with initial metastatic disease, partial remission (PR) was achieved in three patients prior to HDCT. Type of response subsequent to ASCT was complete response (CR) in four patients with initial localised disease and CR in two patients with initial metastatic disease. No patient died within the first 100 days after HDCT. Side effects were rare and manageable. CONCLUSION: This retrospective analysis suggests that ASCT may be considered in patients with metastatic ES, previously treated with standard therapy.
BACKGROUND: Adults with metastatic Ewing family sarcomas (ES) after being treated with standard therapy for localised disease have limited treatment options with curative intent. The aim of this retrospective single centre study was to evaluate the efficacy of autologous stem cell transplantation (ASCT) in this patient population. METHODS: We report on seven consecutive patients with ES. Four patients with initial localised disease developed distant metastases after being treated with initial standard pre-operative chemotherapy followed by surgery and subsequent standard post-operative chemotherapy. Three patients with initial metastatic disease were pre-treated with standard polychemotherapy. All patients received high-dose chemotherapy (HDCT) followed by ASCT for metastatic disease. RESULTS: For patients with initial metastatic disease, partial remission (PR) was achieved in three patients prior to HDCT. Type of response subsequent to ASCT was complete response (CR) in four patients with initial localised disease and CR in two patients with initial metastatic disease. No patient died within the first 100 days after HDCT. Side effects were rare and manageable. CONCLUSION: This retrospective analysis suggests that ASCT may be considered in patients with metastatic ES, previously treated with standard therapy.
Authors: S L Gardner; J Carreras; C Boudreau; B M Camitta; R H Adams; A R Chen; S M Davies; J R Edwards; A C Grovas; G A Hale; H M Lazarus; M Arora; P J Stiff; M Eapen Journal: Bone Marrow Transplant Date: 2008-02-04 Impact factor: 5.483
Authors: M Paulussen; S Ahrens; A W Craft; J Dunst; B Fröhlich; S Jabar; C Rübe; W Winkelmann; S Wissing; A Zoubek; H Jürgens Journal: J Clin Oncol Date: 1998-09 Impact factor: 44.544
Authors: Valérie Laurence; Jean-Yves Pierga; Sophie Barthier; Antoine Babinet; Claire Alapetite; Thao Palangié; Gonzagues de Pinieux; Philippe Anract; Pierre Pouillart Journal: Am J Clin Oncol Date: 2005-06 Impact factor: 2.339
Authors: S Burdach; B van Kaick; H J Laws; S Ahrens; R Haase; D Körholz; H Pape; J Dunst; T Kahn; R Willers; B Engel; U Dirksen; C Kramm; W Nürnberger; A Heyll; R Ladenstein; H Gadner; H Jürgens; U Go el Journal: Ann Oncol Date: 2000-11 Impact factor: 32.976
Authors: B Dockhorn-Dworniczak; K L Schäfer; R Dantcheva; S Blasius; F van Valen; S Burdach; W Winkelmann; H Jürgens; W Böcker Journal: Pathologe Date: 1994-04 Impact factor: 1.011
Authors: J Rosenthal; E Bolotin; M Shakhnovits; A Pawlowska; P Falk; D Qian; C Oliver; J Sato; J Miser; S Forman Journal: Bone Marrow Transplant Date: 2008-06-30 Impact factor: 5.483
Authors: B Kasper; T Lehnert; L Bernd; G Mechtersheimer; H Goldschmidt; A D Ho; G Egerer Journal: Bone Marrow Transplant Date: 2004-07 Impact factor: 5.483